3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Interventions
venetoclax
28
Cytarabine
25
Azacitidine
23
Specimen Handling
21
fludarabine
15
Biopsy
13
Injections
12
Daunorubicin
11
Cyclophosphamide
11
fludarabine phosphate
10
decitabine and cedazuridine drug combination
9
Whole-Body Irradiation
9
CPX-351
8
Mycophenolic Acid
7
Idarubicin
7
Granulocyte Colony-Stimulating Factor
7
Gemtuzumab
7
ivosidenib
6
Tacrolimus
6
Stem Cell Transplantation
6
Filgrastim
6
Busulfan
6
enasidenib
5
X-Rays
5
Melphalan
5
Etoposide
5
Decitabine
5
Cyclosporine
5
ruxolitinib
4
olutasidenib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Myeloid, Acute
×
posaconazole
×
30 days
×
Clear all
NCT07155226
2026-05-19
MOMENTUM
AstraZeneca
Phase 1/2
Recruiting
84 enrolled